Aleksandra Marczak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aleksandra Marczak has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Maria Maciąg
Military Clinical Hospital in Lublin, al. Racławickie 23, 20-049 Lublin, Poland
6 shared publications - Aleksandra Muca
University Clinical Hospital No. 1 in Lublin, ul. Stanisława Staszica 16, 20-081 Lublin, Poland
5 shared publications - Jarosław Pulikowski
4th Clinical University Hospital in Lublin, ul. Kazimierza Jaczewskiego 8, 20-954 Lublin, Poland
5 shared publications - Joanna Baran
St. Vincent de Paul Hospital, ul. Wójta Radtkego 1, 81-348 Gdynia, Poland
5 shared publications - Julia Krawczuk Vel Walczuk
Military Clinical Hospital in Lublin, al. Racławickie 23, 20-049 Lublin, Poland
5 shared publications - Karolina Garbacz
Military Clinical Hospital in Lublin, al. Racławickie 23, 20-049 Lublin, Poland
5 shared publications
Latest Publications
- Open Access
- 13 December 2024
- Published by Medical University of Lublin in Current Problems of Psychiatry
- Vol. 25, 248-254
Gender dysphoria and incongruence - neurophysiological diversity and genetic factors
Introduction: Transgender people may experience gender dysphoria, which is defined as the distress and impairment associated with a person's perception of a marked incongruity between their gender identification and their sex assigned at birth. The aim of the study is to understand the neurophysiological diversity of people with and without dysphoria, as well as to assess the genetic, endocrine and biological basis of the development of dysphoria. Material and methods: A review of the available literature was performed by searching the Google Scholar and PubMed databases using the keywords: dysphoria, gender incongruity, neurophysiology, neurophysiological diversity and dysphoria, gender dysphoria and genetics. This publication is based on a literature review covering the years 2015 - 2023. Works published before 2015 were excluded from the analysis. The SANRA scale was used to maintain the high quality of the narrative review. Results: Gender dysphoria has a polygenic basis, involving interactions between various genes and their polymorphisms. Endocrine factors are also important, so the most complete picture of the neurophysiological basis of gender dysphoria can be obtained by adding brain imaging tests and measurements of sex hormone concentrations to genetic tests. Conclusions: Determining what biological factors contribute to gender dysphoria may have a positive impact on the mental health of transgender people. Moreover, this knowledge can be used to improve the quality of diagnosis and treatment of these people. Therefore, there is a clinical need to conduct further research in this field.
- 13 December 2024
- Published by Medical University of Lublin in Current Problems of Psychiatry
- Vol. 25, 248-254
Open AccessGender dysphoria and incongruence - neurophysiological diversity and genetic factors
Introduction: Transgender people may experience gender dysphoria, which is defined as the distress and impairment associated with a person's perception of a marked incongruity between their gender identification and their sex assigned at birth. The aim of the study is to understand the neurophysiological diversity of people with and without dysphoria, as well as to assess the genetic, endocrine and biological basis of the development of dysphoria. Material and methods: A review of the available literature was performed by searching the Google Scholar and PubMed databases using the keywords: dysphoria, gender incongruity, neurophysiology, neurophysiological diversity and dysphoria, gender dysphoria and genetics. This publication is based on a literature review covering the years 2015 - 2023. Works published before 2015 were excluded from the analysis. The SANRA scale was used to maintain the high quality of the narrative review. Results: Gender dysphoria has a polygenic basis, involving interactions between various genes and their polymorphisms. Endocrine factors are also important, so the most complete picture of the neurophysiological basis of gender dysphoria can be obtained by adding brain imaging tests and measurements of sex hormone concentrations to genetic tests. Conclusions: Determining what biological factors contribute to gender dysphoria may have a positive impact on the mental health of transgender people. Moreover, this knowledge can be used to improve the quality of diagnosis and treatment of these people. Therefore, there is a clinical need to conduct further research in this field.
- Open Access
- 17 November 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 33, 55164
Interrelationships between affective disorders in the form of depression and obesity and overweight - A systematic review
Both depression and obesity are significant health, social and economic problems. Depressive disorders were the second most common psychiatric disorder in 2017 after anxiety disorders. According to data published by the World Health Organization (WHO), depression affects about 280 million people worldwide, which is about 3.8 percent of the population. The etiology of depressive disorders is very complex and still not fully understood. The theories described so far complement each other. The factors underlying the development of depressive disorders can be divided into biological, psychological and other factors. Eating disorders in the form of overweight and obesity result from a loss of balance between anabolic and catabolic processes. This is most often led by insufficient physical activity and excess caloric intake. Hormonal disorders, genetic factors and environmental factors may also play an important role in the pathogenesis of obesity. The steadily increasing number of people suffering from depression and obesity prompts the search for links between these two seemingly unrelated disease entities. According to current knowledge, these diseases are bi-directionally linked by genetic, psychological, metabolic and social factors. Depression is associated with an increase in the risk of obesity by about 37% relative to those without depression. Obesity is associated with an increase in the risk of depressive disorders by about 18%. Understanding the links that exist between depressive disorders and obesity enables the search for new therapeutic options. The most important conclusion from the scientific research conducted so far is the advantage of simultaneous treatment of obesity and depression over treating these disease entities individually.
- 17 November 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 33, 55164
Open AccessInterrelationships between affective disorders in the form of depression and obesity and overweight - A systematic review
Both depression and obesity are significant health, social and economic problems. Depressive disorders were the second most common psychiatric disorder in 2017 after anxiety disorders. According to data published by the World Health Organization (WHO), depression affects about 280 million people worldwide, which is about 3.8 percent of the population. The etiology of depressive disorders is very complex and still not fully understood. The theories described so far complement each other. The factors underlying the development of depressive disorders can be divided into biological, psychological and other factors. Eating disorders in the form of overweight and obesity result from a loss of balance between anabolic and catabolic processes. This is most often led by insufficient physical activity and excess caloric intake. Hormonal disorders, genetic factors and environmental factors may also play an important role in the pathogenesis of obesity. The steadily increasing number of people suffering from depression and obesity prompts the search for links between these two seemingly unrelated disease entities. According to current knowledge, these diseases are bi-directionally linked by genetic, psychological, metabolic and social factors. Depression is associated with an increase in the risk of obesity by about 37% relative to those without depression. Obesity is associated with an increase in the risk of depressive disorders by about 18%. Understanding the links that exist between depressive disorders and obesity enables the search for new therapeutic options. The most important conclusion from the scientific research conducted so far is the advantage of simultaneous treatment of obesity and depression over treating these disease entities individually.
- Open Access
- 17 November 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 31, 55297
role of lipoprotein a in cardiac risk stratification and evaluation of hypolipemizing treatment
Introduction and purpose Cardiovascular diseases are one of the most common causes of death. Due to their popularity and the costs they generate, they are a significant problem. One of the cardiovascular risk factors is the level of lipoprotein(a). Lipoprotein (a) levels are not commonly used to stratify cardiovascular risk, but recommendations suggest that every adult should have them checked. The aim of this study is to discuss current knowledge about the role of lipoprotein (a) in cardiac risk stratification and evaluation of hypolipemizing treatment. Material and methods The PubMed database was used to review the literature. An electronic literature search was conducted, publication years were limited to 2018-2024. Three articles that did not meet this criterion due to their earlier publication dates were included because they served as important sources of information for this article. Keywords were used as search terms. Conclusion Based on the available data, the benefits of lowering lipoprotein(a) levels in the context of cardiovascular diseases cannot be confirmed. There is a need for further research into the role of lipoprotein (a) in stratifying cardiovascular risk, the benefits of lowering its levels, and specific therapeutic approaches for this disorder.
- 17 November 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 31, 55297
Open Accessrole of lipoprotein a in cardiac risk stratification and evaluation of hypolipemizing treatment
Introduction and purpose Cardiovascular diseases are one of the most common causes of death. Due to their popularity and the costs they generate, they are a significant problem. One of the cardiovascular risk factors is the level of lipoprotein(a). Lipoprotein (a) levels are not commonly used to stratify cardiovascular risk, but recommendations suggest that every adult should have them checked. The aim of this study is to discuss current knowledge about the role of lipoprotein (a) in cardiac risk stratification and evaluation of hypolipemizing treatment. Material and methods The PubMed database was used to review the literature. An electronic literature search was conducted, publication years were limited to 2018-2024. Three articles that did not meet this criterion due to their earlier publication dates were included because they served as important sources of information for this article. Keywords were used as search terms. Conclusion Based on the available data, the benefits of lowering lipoprotein(a) levels in the context of cardiovascular diseases cannot be confirmed. There is a need for further research into the role of lipoprotein (a) in stratifying cardiovascular risk, the benefits of lowering its levels, and specific therapeutic approaches for this disorder.
- Open Access
- 22 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54723
role of butyric acid in the human body - review
Wprowadzenie i cel: Kwas masłowy jest jednym z najważniejszych krótkołańcuchowych kwasów tłuszczowych (SCFA) wytwarzanych w ludzkim jelicie grubym. Celem tego artykułu jest podkreślenie jego funkcji i potencjalnych zastosowań w praktyce klinicznej. Analizując wyniki badań i publikacje naukowe, podejmiemy próbę wyjaśnienia znaczenia kwasu masłowego w funkcjonowaniu ludzkiego ciała. Cel pracy: Celem niniejszej pracy było przedstawienie wyników badań naukowych dotyczących funkcji i zastosowania kwasu masłowego w medycynie. Materiały i metody: Niniejszy przegląd opiera się na analizie materiałów pochodzących z bazy PubMed i różnych artykułów naukowych, wykorzystujących takie słowa kluczowe, jak „kwas masłowy”, „maślan”, „nieswoiste zapalenie jelit”, „odporność”, „mikrobiota jelitowa” i „krótkołańcuchowe kwasy tłuszczowe”. Opis stanu wiedzy: Mikrobiota jelitowa jest przedmiotem badań naukowych od wielu lat, jednak znaczenie jej produktów metabolicznych, w tym kwasu masłowego, jest dopiero teraz w pełni zrozumiane. Obecny stan wiedzy daje nadzieję na stosowanie kwasu masłowego w takich schorzeniach jak choroby zapalne jelit, co potwierdzają liczne badania. Przeciwzapalne właściwości tego metabolitu bakterii jelitowych sugerują również potencjalne korzyści w chorobach neurodegeneracyjnych i sercowo-naczyniowych, co podkreślają cytowane tutaj prace naukowe, które potwierdzają takie zastosowania . Wnioski : Kwas masłowy, jako produkt metaboliczny mikrobiomu jelitowego, ma potencjał, aby stać się znaczącym suplementem w różnych dziedzinach medycyny. Niniejszy przegląd, który bada jego działania i zastosowania, dostarcza wglądu w jego możliwe funkcje i daje nadzieję na przyszłe opcje terapeutyczne.
- 22 September 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 22, 54723
Open Accessrole of butyric acid in the human body - review
Wprowadzenie i cel: Kwas masłowy jest jednym z najważniejszych krótkołańcuchowych kwasów tłuszczowych (SCFA) wytwarzanych w ludzkim jelicie grubym. Celem tego artykułu jest podkreślenie jego funkcji i potencjalnych zastosowań w praktyce klinicznej. Analizując wyniki badań i publikacje naukowe, podejmiemy próbę wyjaśnienia znaczenia kwasu masłowego w funkcjonowaniu ludzkiego ciała. Cel pracy: Celem niniejszej pracy było przedstawienie wyników badań naukowych dotyczących funkcji i zastosowania kwasu masłowego w medycynie. Materiały i metody: Niniejszy przegląd opiera się na analizie materiałów pochodzących z bazy PubMed i różnych artykułów naukowych, wykorzystujących takie słowa kluczowe, jak „kwas masłowy”, „maślan”, „nieswoiste zapalenie jelit”, „odporność”, „mikrobiota jelitowa” i „krótkołańcuchowe kwasy tłuszczowe”. Opis stanu wiedzy: Mikrobiota jelitowa jest przedmiotem badań naukowych od wielu lat, jednak znaczenie jej produktów metabolicznych, w tym kwasu masłowego, jest dopiero teraz w pełni zrozumiane. Obecny stan wiedzy daje nadzieję na stosowanie kwasu masłowego w takich schorzeniach jak choroby zapalne jelit, co potwierdzają liczne badania. Przeciwzapalne właściwości tego metabolitu bakterii jelitowych sugerują również potencjalne korzyści w chorobach neurodegeneracyjnych i sercowo-naczyniowych, co podkreślają cytowane tutaj prace naukowe, które potwierdzają takie zastosowania . Wnioski : Kwas masłowy, jako produkt metaboliczny mikrobiomu jelitowego, ma potencjał, aby stać się znaczącym suplementem w różnych dziedzinach medycyny. Niniejszy przegląd, który bada jego działania i zastosowania, dostarcza wglądu w jego możliwe funkcje i daje nadzieję na przyszłe opcje terapeutyczne.
- Open Access
- 22 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 70, 49802
Does sauna bathing prevent chronic obstructive pulmonary disease or Alzheimer's disease? May adults with cardiovascular disease use a sauna? A systematic review
Recently, there has been a surge of interest in sauna bathing and its role in health aspects. However, there are few studies focusing on the association between regular sauntering and the risk of dementia and chronic obstructive pulmonary disease (COPD). Considerably better understood are the effects on the cardiovascular system. This study delves into contemporary scientific research on Finnish saunas, exploring their potential correlation with Alzheimer's disease prevention, their impact on vascular health in adults with cardiovascular disorders, and their association with reducing the risk of chronic obstructive pulmonary disease. Scientific studies published in PubMed, Scopus and Google Scholar databases were analyzed, including terms related to Finnish sauna, dementia, COPD and cardiovascular disease. The methodological quality and results of each study were evaluated. Sauna bathing in addition to being a relaxing lifestyle habit, remains a potential additional strategy which can be used in improving cardiovascular function in adults with well-controlled cardiovascular disorders. A limited amount of research has been identified on the correlation between sauna bathing and reduced risk of Alzheimer's disease and COPD. The accumulating evidence suggests that frequent sauna bathing may reduce the risk or severity of several vascular and nonvascular conditions including COPD and also moderate to high frequency of sauna bathing was associated with lowered risks of dementia and Alzheimer’s disease. Further research is required, especially large-scale cohort studies with repeated measurement on sauna to establish the potential mechanisms linking sauna bathing and either memory diseases or COPD and better understand the relationship between sauntering and cardiovascular health. Upcoming studies may become very promising for the development of sauna bathing as a new non-pharmacological treatment or prevention of various diseases and improvement in the quality of life.
- 22 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 70, 49802
Open AccessDoes sauna bathing prevent chronic obstructive pulmonary disease or Alzheimer's disease? May adults with cardiovascular disease use a sauna? A systematic review
Recently, there has been a surge of interest in sauna bathing and its role in health aspects. However, there are few studies focusing on the association between regular sauntering and the risk of dementia and chronic obstructive pulmonary disease (COPD). Considerably better understood are the effects on the cardiovascular system. This study delves into contemporary scientific research on Finnish saunas, exploring their potential correlation with Alzheimer's disease prevention, their impact on vascular health in adults with cardiovascular disorders, and their association with reducing the risk of chronic obstructive pulmonary disease. Scientific studies published in PubMed, Scopus and Google Scholar databases were analyzed, including terms related to Finnish sauna, dementia, COPD and cardiovascular disease. The methodological quality and results of each study were evaluated. Sauna bathing in addition to being a relaxing lifestyle habit, remains a potential additional strategy which can be used in improving cardiovascular function in adults with well-controlled cardiovascular disorders. A limited amount of research has been identified on the correlation between sauna bathing and reduced risk of Alzheimer's disease and COPD. The accumulating evidence suggests that frequent sauna bathing may reduce the risk or severity of several vascular and nonvascular conditions including COPD and also moderate to high frequency of sauna bathing was associated with lowered risks of dementia and Alzheimer’s disease. Further research is required, especially large-scale cohort studies with repeated measurement on sauna to establish the potential mechanisms linking sauna bathing and either memory diseases or COPD and better understand the relationship between sauntering and cardiovascular health. Upcoming studies may become very promising for the development of sauna bathing as a new non-pharmacological treatment or prevention of various diseases and improvement in the quality of life.
- Open Access
- 21 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 62, 61-75
Lichen planus: A Systematic Review
Lichen planus (LP) is a chronic skin, mucous membrane, and nail disease. Lichen planus is a rare skin condition occurring in less than 1% of the general population, affecting both children and adults. Oral lichen planus (OLP) involvement is much more common. It is an autoimmune disease caused by T lymphocytes, with epigenetic factors playing a significant role in the development of autoimmune skin diseases. MicroRNAs (miRNAs), a group of non-coding RNAs, play a substantial role in regulating the immune response.1 The etiology of lichen planus in not fully understood. It can be triggered by antihypertensive drugs, beta-blockers, infections, viral hepatitis, psychological stress, and others. Cases of lichen planus appearing after recovering from COVID-19 have been reported, as well as a significant increase in cases after COVID-19 vaccination.2–5 Diagnosis is based on clinical presenstation and characteristic histopathological findings. The disease is often self-limiting, accompanied by persistent itching and painful erosions of the mucous membrane, affecting the patient’s quality of life and mental well-being. First-line treatments inculde topical corticosteroids and/or oral corticosteroids. There are reports of new potential treatments, such as biologic drugs (anti-IL12/13, anti-IL17) and Janus kinase inhibitors. Consequently, a dramatic change in lichen planus treatment can be expected in the near future. The majority of patients suffering from lichen planus develop metabolic syndrome which is the cause of other diseases. This article provides a comprehensive overview of current knowledge about lichen planus and its variants.
- 21 February 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 62, 61-75
Open AccessLichen planus: A Systematic Review
Lichen planus (LP) is a chronic skin, mucous membrane, and nail disease. Lichen planus is a rare skin condition occurring in less than 1% of the general population, affecting both children and adults. Oral lichen planus (OLP) involvement is much more common. It is an autoimmune disease caused by T lymphocytes, with epigenetic factors playing a significant role in the development of autoimmune skin diseases. MicroRNAs (miRNAs), a group of non-coding RNAs, play a substantial role in regulating the immune response.1 The etiology of lichen planus in not fully understood. It can be triggered by antihypertensive drugs, beta-blockers, infections, viral hepatitis, psychological stress, and others. Cases of lichen planus appearing after recovering from COVID-19 have been reported, as well as a significant increase in cases after COVID-19 vaccination.2–5 Diagnosis is based on clinical presenstation and characteristic histopathological findings. The disease is often self-limiting, accompanied by persistent itching and painful erosions of the mucous membrane, affecting the patient’s quality of life and mental well-being. First-line treatments inculde topical corticosteroids and/or oral corticosteroids. There are reports of new potential treatments, such as biologic drugs (anti-IL12/13, anti-IL17) and Janus kinase inhibitors. Consequently, a dramatic change in lichen planus treatment can be expected in the near future. The majority of patients suffering from lichen planus develop metabolic syndrome which is the cause of other diseases. This article provides a comprehensive overview of current knowledge about lichen planus and its variants.
- Open Access
- 8 September 2023
- Published by Medical University of Lublin in Current Problems of Psychiatry
- Vol. 24, 192-198
The meaning of lithium and naltrexone pharmacotherapy in the treatment of borderline personality disorder – a narrative review
Introduction: Borderline personality disorder (BPD) affects approximately 1%-3% of the population. As the most common personality disorder, BPD features behavioural, emotional and social dysfunctions. It often co-occurs with self-harm, suicidal tendencies and substance abuse. To date, pharmacological treatment does not provide sufficient therapeutic effects. The aim of our study is to analyse the neurobiological, genetic and environmental components in the aetiopathogenesis of BPD and to collect data on the innovative use of lithium and naltrexone in the therapy of BPD. Methods: Basing on PubMed and Google Scholar databases using the following keywords: borderline, lithium, naltrexone for papers published from 1979 to 2022. Results: Difficult childhood, and emotional, sexual and physical abuse are the strongest predictors of BPD development. The core symptoms of BPD may be related to dysfunction of the serotonin, dopaminergic, endogenous system and opioid systems. Variation in 5-HTT, COMT, FKBP5 and oxytocin receptor genes may influence the course of BPD. Imaging studies have shown structural and functional abnormalities in the prefrontal cortex, amygdala and hippocampus. Lithium reduces impulsivity, aggression, suicidal tendencies and self-harm in BPD. Naltrexone may effectively reduce self-harm without suicidal tendencies, impulsivity, substance abuse and suicidality. Conclusions: No unified model has been developed to account for environmental, genetic and neurobiological components in the pathogenesis of BPD. Understanding the mechanisms is a crucial step towards personalising treatment. The use of lithium and naltrexone may have positive therapeutic effects. Randomised clinical trials are required to establish the efficacy and safety of both drugs in long-term treatment. Keywords: borderline, lithium, naltrexone
- 8 September 2023
- Published by Medical University of Lublin in Current Problems of Psychiatry
- Vol. 24, 192-198
Open AccessThe meaning of lithium and naltrexone pharmacotherapy in the treatment of borderline personality disorder – a narrative review
Introduction: Borderline personality disorder (BPD) affects approximately 1%-3% of the population. As the most common personality disorder, BPD features behavioural, emotional and social dysfunctions. It often co-occurs with self-harm, suicidal tendencies and substance abuse. To date, pharmacological treatment does not provide sufficient therapeutic effects. The aim of our study is to analyse the neurobiological, genetic and environmental components in the aetiopathogenesis of BPD and to collect data on the innovative use of lithium and naltrexone in the therapy of BPD. Methods: Basing on PubMed and Google Scholar databases using the following keywords: borderline, lithium, naltrexone for papers published from 1979 to 2022. Results: Difficult childhood, and emotional, sexual and physical abuse are the strongest predictors of BPD development. The core symptoms of BPD may be related to dysfunction of the serotonin, dopaminergic, endogenous system and opioid systems. Variation in 5-HTT, COMT, FKBP5 and oxytocin receptor genes may influence the course of BPD. Imaging studies have shown structural and functional abnormalities in the prefrontal cortex, amygdala and hippocampus. Lithium reduces impulsivity, aggression, suicidal tendencies and self-harm in BPD. Naltrexone may effectively reduce self-harm without suicidal tendencies, impulsivity, substance abuse and suicidality. Conclusions: No unified model has been developed to account for environmental, genetic and neurobiological components in the pathogenesis of BPD. Understanding the mechanisms is a crucial step towards personalising treatment. The use of lithium and naltrexone may have positive therapeutic effects. Randomised clinical trials are required to establish the efficacy and safety of both drugs in long-term treatment. Keywords: borderline, lithium, naltrexone
- Open Access
- 8 October 2022
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 12 (10) , 327-334
Atypical age of onset of the small bowel adenocarcinoma – case report
Background: Small bowel adenocarcinoma is a rare malignant tumor, with the typical age of diagnosis being 60 years old. In the field of risk factors, we can distinguish, between genetic disorders, inflammatory bowel diseases, smoking, and alcohol abuse. Guidelines for the screening methods are very wide, hence it may be difficult to make the right diagnosis at the early stages of cancer. Additional difficulties can be caused by similarities to inflammatory processes in the gastrointestinal tract. Case report: We present a case of a 22-year-old male patient, with the symptoms of weight loss, stool retention, abdominal pain, and vomiting. The patient was initially misdiagnosed with inflammatory bowel disease and received the first dose of anti-inflammatory treatment. At that point, the diagnostic process and the workflow of medical care were delayed due to the COVID-19 pandemic. After receiving the x-ray and computed tomography, the obstruction of the ileum was found, and an urgent operation was performed. Tissue samples obtained during surgery revealed the proper diagnosis, a low-differentiated adenocarcinoma (G3) of the small intestine, stage T4Nx. Conclusion: Taking into consideration the patient’s condition, age, and symptoms, we should always think about the probable malignant process. Inflammatory diseases are known for increasing cancer risk and should always be the indication of this disease. The age of onset of the disease is very unusual, however, we must be aware of such cases in our clinical practice.
- 8 October 2022
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 12 (10) , 327-334
Open AccessAtypical age of onset of the small bowel adenocarcinoma – case report
Background: Small bowel adenocarcinoma is a rare malignant tumor, with the typical age of diagnosis being 60 years old. In the field of risk factors, we can distinguish, between genetic disorders, inflammatory bowel diseases, smoking, and alcohol abuse. Guidelines for the screening methods are very wide, hence it may be difficult to make the right diagnosis at the early stages of cancer. Additional difficulties can be caused by similarities to inflammatory processes in the gastrointestinal tract. Case report: We present a case of a 22-year-old male patient, with the symptoms of weight loss, stool retention, abdominal pain, and vomiting. The patient was initially misdiagnosed with inflammatory bowel disease and received the first dose of anti-inflammatory treatment. At that point, the diagnostic process and the workflow of medical care were delayed due to the COVID-19 pandemic. After receiving the x-ray and computed tomography, the obstruction of the ileum was found, and an urgent operation was performed. Tissue samples obtained during surgery revealed the proper diagnosis, a low-differentiated adenocarcinoma (G3) of the small intestine, stage T4Nx. Conclusion: Taking into consideration the patient’s condition, age, and symptoms, we should always think about the probable malignant process. Inflammatory diseases are known for increasing cancer risk and should always be the indication of this disease. The age of onset of the disease is very unusual, however, we must be aware of such cases in our clinical practice.
- 1 September 2020
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 10 (9) , 183-199
Male hypogonadism with its systemic complications
Introduction and purpose: Total lack of testosterone or its level lower than 9-12 mmol/L (250-350 ng/dL) of serum in men is called hypogonadism. Due to the importance of testosterone in male body, hypogonadism usually causes a variety of symptoms, mostly of sexual nature – lack of libido, erectile dysfunction, infertility and associated psychological problems, it can though be the cause of more dangerous changes in the male body. The purpose of this study is to review possible systemic complications of male hypogonadism (with the emphasis on hypogonadotropic hypogonadism) apart from those sex-related.State of knowledge: The lack of testosterone and gonadotropins was proven to cause a number of negative changes in different systems and various clinical situations. It can negatively impact the condition of skeletal system. Although testosterone is widely thought to increase cardiovascular risk some studies show that the hypogonadism has a negative impact on it as well. Some studies hypothesised the role of hypogonadism in anaemia development, but generally it isn’t taken into account in investigation of this condition. Some studies show the impact of hypogonadism on higher risk of some metabolic and endocrine diseases. The most interesting conclusions were found in literature on oncological implications of testosterone and lack of it. It turns out that there is a number of studies showing the positive impact of relatively higher testosterone concentrations while androgen deprivation therapy is the main therapeutic option in advanced prostate cancer.Conclusions: Due to very unpleasant and possibly dangerous complications of hypogonadism endocrinologists should stay alert to signs of hypogonadism to be able to start testosterone replacement in the right moment.
- 1 September 2020
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 10 (9) , 183-199
Male hypogonadism with its systemic complications
Introduction and purpose: Total lack of testosterone or its level lower than 9-12 mmol/L (250-350 ng/dL) of serum in men is called hypogonadism. Due to the importance of testosterone in male body, hypogonadism usually causes a variety of symptoms, mostly of sexual nature – lack of libido, erectile dysfunction, infertility and associated psychological problems, it can though be the cause of more dangerous changes in the male body. The purpose of this study is to review possible systemic complications of male hypogonadism (with the emphasis on hypogonadotropic hypogonadism) apart from those sex-related.State of knowledge: The lack of testosterone and gonadotropins was proven to cause a number of negative changes in different systems and various clinical situations. It can negatively impact the condition of skeletal system. Although testosterone is widely thought to increase cardiovascular risk some studies show that the hypogonadism has a negative impact on it as well. Some studies hypothesised the role of hypogonadism in anaemia development, but generally it isn’t taken into account in investigation of this condition. Some studies show the impact of hypogonadism on higher risk of some metabolic and endocrine diseases. The most interesting conclusions were found in literature on oncological implications of testosterone and lack of it. It turns out that there is a number of studies showing the positive impact of relatively higher testosterone concentrations while androgen deprivation therapy is the main therapeutic option in advanced prostate cancer.Conclusions: Due to very unpleasant and possibly dangerous complications of hypogonadism endocrinologists should stay alert to signs of hypogonadism to be able to start testosterone replacement in the right moment.
- 1 September 2020
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 10 (9) , 143-160
Male hypogonadotropic hypogonadism in various genetic disorders
Introduction and purpose: Male hypogonadism is diagnosed in patients with total testosterone under 9-12nmol/L (250-350ng/dl) in serum which is associated with numerous symptoms which can severely lower the quality of patients life. Due to the cause and associated levels of gonadotropins it can be divided to hypergonadotropic and hypogonadotropic hypogonadism. Hypogonadotropic hypogonadism occurs far less often, but it’s considered to remain underdiagnosed. The purpose of this study is to review most of the inborn diseases that involve hypogonadotropic hypogonadism as one of their components. Current state of knowledge: Patients with Kallmann syndrome constitute the majority of confirmed hypogonadotropic hypogonadism cases, however due to variable epidemiological data and differing diagnosing processes the exact incidence cannot be estimated – it ranges from 1 in 85 000, to 1 in 5000 males and about 3-4 times less often in women. Other conditions that can occur with hypogonadotropic hypogonadism are Isolated Gonadotropin-Releasing Hormone deficiency, Gonadotropin disorders, Prader-Willi Syndrome, some pleiotropic syndromes like CHARGE syndrome, Patau syndrome, Pfeiffer syndrome, Hartsfield syndrome, Waardenburg syndrome, Bardet-Biedl syndrome, or other syndromes. The evaluation and treatment of some of these conditions does not involve hypogonadism or other gonadal disorders due to short lifespan, which cause the underestimations in hypogonadism morbidity. Conclusions: Regardless of lower incidence of hypogonadotropic hypogonadism compared to hypergonadotropic type, endocrinologists should stay aware of its under-diagnosis and actively search for signs of low gonadotropic hormones and gonadotropin-releasing hormone levels in hypogonadal patients.
- 1 September 2020
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 10 (9) , 143-160
Male hypogonadotropic hypogonadism in various genetic disorders
Introduction and purpose: Male hypogonadism is diagnosed in patients with total testosterone under 9-12nmol/L (250-350ng/dl) in serum which is associated with numerous symptoms which can severely lower the quality of patients life. Due to the cause and associated levels of gonadotropins it can be divided to hypergonadotropic and hypogonadotropic hypogonadism. Hypogonadotropic hypogonadism occurs far less often, but it’s considered to remain underdiagnosed. The purpose of this study is to review most of the inborn diseases that involve hypogonadotropic hypogonadism as one of their components. Current state of knowledge: Patients with Kallmann syndrome constitute the majority of confirmed hypogonadotropic hypogonadism cases, however due to variable epidemiological data and differing diagnosing processes the exact incidence cannot be estimated – it ranges from 1 in 85 000, to 1 in 5000 males and about 3-4 times less often in women. Other conditions that can occur with hypogonadotropic hypogonadism are Isolated Gonadotropin-Releasing Hormone deficiency, Gonadotropin disorders, Prader-Willi Syndrome, some pleiotropic syndromes like CHARGE syndrome, Patau syndrome, Pfeiffer syndrome, Hartsfield syndrome, Waardenburg syndrome, Bardet-Biedl syndrome, or other syndromes. The evaluation and treatment of some of these conditions does not involve hypogonadism or other gonadal disorders due to short lifespan, which cause the underestimations in hypogonadism morbidity. Conclusions: Regardless of lower incidence of hypogonadotropic hypogonadism compared to hypergonadotropic type, endocrinologists should stay aware of its under-diagnosis and actively search for signs of low gonadotropic hormones and gonadotropin-releasing hormone levels in hypogonadal patients.